fibroblast growth factor 23 (FGF23) in plasma

Clinical significance

• plasma levels elevated in tumor-induced osteomalacia
• plasma levels elevated in hypophosphatemic rickets
• higher plasma FGF-23 associated with increased risk for coronary artery disease
• plasma levels after stabilization from acute coronary syndrome associated with increased risk of major CV events (RR=1.4) & all-cause mortality (RR=2.3)
  • more so in men than women
    • risk of CV death or heart failure (RR=3.1 vs 1.1 men vs women)
• associated with myocardial fibrosis
• associated with upregulation of renin-angiotensin system
• high levels associated with secondary hyperparathyroidism & tertiary hyperparathyroidism
  • elevated FGF-23 & PTH promote phosphorus excretion

Methods

• plasma C-terminal FGF-23 concentration

More general terms

• fibroblast growth factor (FGF) in serum/plasma

Additional terms

• fibroblast growth factor 23; FGF-23; phosphatonin; tumor-derived hypophosphatemia-inducing factor; contains: fibroblast growth factor 23 N-terminal peptide; fibroblast growth factor 23 C-terminal peptide (FGF23, HYPF, UNQ3027/PRO9828)